Comparative Pharmacology
Head-to-head clinical analysis: EVEROLIMUS versus FYARRO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EVEROLIMUS versus FYARRO.
EVEROLIMUS vs FYARRO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase. It binds to FKBP-12, forming a complex that inhibits mTOR complex 1 (mTORC1) signaling, reducing cell proliferation, angiogenesis, and glucose uptake.
FYARRO (sirolimus protein-bound particles for injectable suspension) is an mTOR inhibitor. Sirolimus binds to FKBP-12 and inhibits mTOR complex 1 (mTORC1), reducing phosphorylation of downstream effectors such as S6K1 and 4E-BP1, thereby inhibiting cell growth, proliferation, and angiogenesis.
10 mg orally once daily for advanced RCC or pancreatic NET; 10 mg orally once daily for subependymal giant cell astrocytoma; 5 mg orally once daily for renal angiomyolipoma. For breast cancer: 10 mg orally once daily with exemestane 25 mg orally daily. For renal transplant rejection prophylaxis: 0.75 mg (maximum 1.5 mg) orally twice daily with cyclosporine and corticosteroids, with therapeutic drug monitoring (trough 3-8 ng/mL).
Recommended dose is 100 mg/m² (up to 200 mg maximum) administered as an intravenous infusion over 30 minutes once weekly on days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxicity.
None Documented
Clinical Note
moderateEverolimus + Digoxin
"The serum concentration of Digoxin can be increased when it is combined with Everolimus."
Clinical Note
moderateEverolimus + Digitoxin
"Everolimus may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateEverolimus + Deslanoside
"Everolimus may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateEverolimus + Acetyldigitoxin
"Everolimus may decrease the cardiotoxic activities of Acetyldigitoxin."
None Documented
Terminal half-life ~30 hours (range 26–38 h) in stable renal transplant patients; supports once-daily dosing.
Approximately 53 hours (terminal elimination half-life), supporting once-weekly IV administration.
Primarily fecal (80%) with 5% renal excretion as metabolites; unchanged drug minimal in urine.
Primarily via biliary/fecal excretion (approximately 77% of the dose recovered in feces as metabolites); renal excretion accounts for approximately 18%.
Category D/X
Category C
mTOR Inhibitor
mTOR Inhibitor